


**Amendments to the Claims:**

This Listing of Claims will replace all prior versions and listings of claims in the application.

**Listing Of Claims**

1.(currently amended) A method of treating mammary carcinoma, wherein the method comprises administering a therapeutically effective amount of an alkylphosphocholine compound of the general Formula II:



in which, independently of one another,

n, m, p, z is a whole number between 0 and 4;

x is O, S, NH;


R is hydrogen, a linear or branched C<sub>1</sub> to C<sub>20</sub> alkyl group, which may be saturated or unsaturated with one to three double and/or triple bonds and unsubstituted or optionally substituted at the same or at different carbon atoms with one, two or more halogen, nitro, cyano, hydroxy, C<sub>1</sub> to C<sub>6</sub> alkoxy, amino, mono-(C<sub>1</sub> to C<sub>4</sub>) alkylamino or di-(C<sub>1</sub> to C<sub>4</sub>) alkylamino groups;

R<sub>1</sub>, R<sub>2</sub> independently of one another represent hydrogen, a linear or branched (C<sub>1</sub> to C<sub>6</sub>) alkyl group, preferably methyl and ethyl, a (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl group, which may be unsubstituted or optionally substituted at the same or different carbon atoms with one, two or more halogen, nitro, cyano, hydroxy, C<sub>1</sub> to C<sub>6</sub> alkoxy, amino, mono-(C<sub>1</sub> to C<sub>4</sub>) alkylamino or di-(C<sub>1</sub> to C<sub>4</sub>) alkylamino groups and pharmaceutically acceptable salts thereof; wherein said alkylphosphocholine is administered before and/or during treatment with an

antimetabolite approved antitumor substance chosen from-earboplatnum,  
oxaliplatinum, bleomycin, methotrexate, paclitaxel, docetaxel, vineristine,  
vinblastine, etoposide, teniposide, ifosfamide, 5-fluorouracil, fludarabin,  
gemcitabine and cytarabine.

2. (canceled)

3. (currently amended) A method of treating mammary carcinoma, wherein said method  
comprises administering a therapeutically effective amount of an alkylphosphocholine  
compound of the general Formula II:



where, independently of one another,

m, p are the integer 1;

n, z are the integer 2;

x is O;

R is H or a straight-chain or branched (C<sub>1</sub>-C<sub>17</sub>)-alkyl group which may be saturated  
or unsaturated with one to three double and/or triple bonds;

R<sub>1</sub>, R<sub>2</sub> are, independently of one another, H or a straight-chain or branched (C<sub>1</sub>-  
C<sub>6</sub>)alkyl group, preferably methyl and ethyl, a (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl group;

wherein said alkylphosphocholine is administered before and/or during treatment  
with an antimetabolite approved antitumor substance chosen from  
earboplatnum, oxaliplatinum, bleomycin, methotrexate, paclitaxel, docetaxel,  
vineristine, vinblastine, etoposide, teniposide, ifosfamide, 5-fluorouracil,  
fludarabin, gemcitabine and cytarabine.

4. (currently amended) A method of treating mammary carcinoma, wherein said method comprises administering a therapeutically effective amount of octadecyl 1,1-dimethyl

4. (currently amended) A method of treating mammary carcinoma, wherein said method comprises administering a therapeutically effective amount of octadecyl 1,1-dimethylpiperidinium-4-yl phosphate (perifosine) as claimed in claim 1 wherein said alkylphosphocholine is administered before and/or during treatment with an antimetabolite approved antitumor substance chosen from carboplatinum, oxaliplatinum, bleomycin, methotrexate, paclitaxel, docetaxel, vinceristine, vinblastine, etoposide, teniposide, ifosfamide, 5-fluorouracil, fludarabin, gemcitabine and cytarabine.

Claim 5. (canceled)

Claim 6. (canceled)

Claim 7. (canceled)

Claim 8 (canceled)

Claim 9 (canceled)

Claim 10 (canceled)

Claim 11 (canceled)

Claim 12. (currently amended) A drug product consisting essentially of an alkylphosphocholine of the general Formula II as in claims 1, 3, or 4 and, where appropriate, carriers and/or excipients for use in the treatment of mammary carcinoma wherein the drug product is administered before and/or during the treatment with an approved antitumor substance chosen from carboplatinum, oxaliplatinum, bleomycin, methotrexate, paclitaxel, docetaxel, vinceristine, vinblastine, etoposide, teniposide, ifosfamide, 5-fluorouracil, fludarabin, gemcitabine and cytarabine.

Claim 13 (canceled)